Clinical trials: Advanced Esophageal Cancer
Esophageal Cancer
Radiation Therapy and Combination Chemotherapy With or Without Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Trial name
- NCT00416858
- Testing
- cisplatin, fluorouracil, adjuvant therapy
- Volunteers
- 40 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer
Patients with unresectable or metastatic gastric or esophageal cancer, with first-line treatment applied are to be recruited in the study.
- Trial name
- OASIS (NCT04503967)
- Testing
- Anlotinib Hydrochloride With Nivolumab
- Volunteers
- 48 people
- Sponsor
- Shanghai Zhongshan Hospital
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Gastrointestinal Cancer, Colorectal Cancer
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers
The purpose of the study is to determine whether standardized implementation of a scripted template for discussing important issues that arise near the end of life improves the care of those who have advanced cancer.
- Conditions
- Gastrointestinal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer
- Trial name
- NCT04077372
- Testing
- Serious Illness Conversation Guide (SICG), Quality of Life (QOL) survey
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University
Cancer, Solid Tumor
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Trial name
- NCT05500508
- Testing
- AMXT1501, DFMO
- Where
- 7 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Aminex Therapeutics, Inc.
Pancreatic Cancer, Small Bowel Cancer
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF…
- Conditions
- Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma
- Trial name
- NCT04566393
- Testing
- Ulixertinib (BVD-523)
- Where
- 26 sites in United States
- Sponsor
- xCures
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Esophageal Squamous Cell Carcinoma, Immunotherapy
Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC.
Conduct a retrospective and prospective study to confirm the association between blood cells counts and the efficacy and safety in immunochemotherapy in patients with advanced esophageal cancer.
- Conditions
- Esophageal Squamous Cell Carcinoma, Immunotherapy, Chemotherapy
- Trial name
- NCT06125262
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guangdong Provincial People's Hospital
Oesophageal Adenocarcinoma, T Cells
Will a Pre-therapy Exercise Intervention Improve the Outcomes of Patients With Advanced Oesophageal Cancer?
Background Regular exercise can significantly improve physical and mental health during cancer treatment and reduce the time needed in the hospital.
- Conditions
- Oesophageal Adenocarcinoma, T Cells, Tumor Microenvironment, Exercise
- Trial name
- OPTIMUS (NCT07375420)
- Testing
- Low intensity exercise, High intensity exercise
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Surrey
Esophageal Neoplasms
Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer
The combination of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor has shown efficacy in many cancers.The purpose of this study is to confirm that the combination of these two drugs can benefit patients with advanced…
- Trial name
- AIPAAIAEC (NCT05349045)
- Testing
- an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Advanced Cancers
Randomized Trial of Glutamine in Patients With Mucositis or Esophagitis
The goal of this clinical research study is to learn if glutamine can help control and prevent sores, blisters, or inflammation in your mouth or esophagus due to your current treatment.
- Trial name
- NCT01952847
- Testing
- Glutamine, Questionnaires
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer, Sarcoma
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide/fludarabine (CY/FLU) and supported with low-dose IL-15…
- Conditions
- Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- EBNK-ST-001 (NCT07410676)
- Testing
- EBNK-001 + IL-15 + Pembrolizumab
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Essen Biotech
Esophageal Carcinoma (Squamous Cell Carcinoma - Adenocarcinoma)
Early Metabolic Response in Locally Advanced Esophageal Cancer Undergoing Induction Chemoradiotherapy
Early metabolic response evaluation may predict clinical and histopathological response after neoadjuvant chemotherapy. Its value in neoadjuvant chemoradiotherapy (CRT) is unknown.
- Trial name
- NCT01269970
- Testing
- 18-FDG-PET-CT
- Where
- Belgium
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Esophageal Squamous Cell Carcinoma (ESCC), Infiltration
Infiltration Pattern of Locally Advanced ESCC
Prospectively collect the pathological records of ESCC patients, and analyse the infiltration pattern of ESCC.
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Infiltration, Tumour
- Trial name
- NCT07567716
- Testing
- Esophagectomy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Chest Hospital
Esophageal Cancer
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer
The purpose of this study is to provide access to paclitaxel therapy to subjects with advanced or recurrent esophageal cancer who have completed the previous Phase 2 study (CA139-540) and who should continue on therapy with…
- Trial name
- NCT00971841
- Testing
- Paclitaxel
- Volunteers
- 1 people
- Sponsor
- Bristol-Myers Squibb
Oesophageal Cancer
ROCS (Radiotherapy After Oesophageal Cancer Stenting) Study
The single most distressing symptom for more than 70% of patients with oesophageal cancer is difficulty in swallowing (dysphagia) caused by blockage of the gullet by a tumour.
- Trial name
- ROCS (NCT01915693)
- Testing
- Radiotherapy
- Where
- 17 sites in United Kingdom
- Volunteers
- 220 people
- Sponsor
- Lisette Nixon
Esophageal Cancer, Gastric Cancer
Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00524186
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Roswell Park Cancer Institute
Esophageal Cancer
Anlotinib for Esophageal Cancer (AFEC)
The purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced esophageal cancer in the real world, and to summarize the…
- Trial name
- NCT04966611
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Anyang Tumor Hospital
Stomach Cancer, Stomach Cancer Recurrent
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
This Phase I/II study evaluates the safety and efficacy of autologous tumor-infiltrating lymphocytes (TIL) therapy combined with Pembrolizumab (Keytruda) immunotherapy in patients with advanced or metastatic refractory stomach…
- Conditions
- Stomach Cancer, Stomach Cancer Recurrent, Stomach Cancer, Adenocarcinoma, Esophageal Cancer
- Trial name
- BAH250 (NCT06532799)
- Testing
- Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamid, Fludarabine
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Essen Biotech
Esophageal Cancer, Gastric Cancer
Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.
- Trial name
- NCT00032123
- Testing
- erlotinib hydrochloride
- Where
- 107 sites in United States, Canada
- Sponsor
- SWOG Cancer Research Network